schliessen

Filtern

 

Bibliotheken

Effect of Erythropoietin on Urinary Liver-Type Fatty-Acid-Binding Protein in Patients with Chronic Renal Failure and Anemia

Background/Aim: The urinary liver-type fatty-acid-binding protein (L-FABP) level reflects the clinical progression of chronic kidney disease. We conducted a study to determine whether administration of erythropoietin (EPO), which is produced in response to hypoxic stress, affects urinary protein exc... Full description

Journal Title: American journal of nephrology 2006, Vol.26 (3), p.276-280
Main Author: Nakamura, Tsukasa
Other Authors: Sugaya, Takeshi , Kawagoe, Yasuhiro , Suzuki, Tsukasa , Ueda, Yoshihiko , Koide, Hikaru
Format: Electronic Article Electronic Article
Language: English
Subjects:
Quelle: Alma/SFX Local Collection
Publisher: Basel, Switzerland: Karger
ID: ISSN: 0250-8095
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: cdi_proquest_journals_236943470
title: Effect of Erythropoietin on Urinary Liver-Type Fatty-Acid-Binding Protein in Patients with Chronic Renal Failure and Anemia
format: Article
creator:
  • Nakamura, Tsukasa
  • Sugaya, Takeshi
  • Kawagoe, Yasuhiro
  • Suzuki, Tsukasa
  • Ueda, Yoshihiko
  • Koide, Hikaru
subjects:
  • Adult
  • Aged
  • Anemia - etiology
  • Anemia - prevention & control
  • Anemia - urine
  • Anemias. Hemoglobinopathies
  • Biological and medical sciences
  • Diseases of red blood cells
  • Erythropoietin - therapeutic use
  • Fatty Acid-Binding Proteins - urine
  • Female
  • Hematologic and hematopoietic diseases
  • Hemoglobins - analysis
  • Humans
  • Kidney Failure, Chronic - complications
  • Kidney Failure, Chronic - drug therapy
  • Kidney Failure, Chronic - urine
  • Male
  • Medical sciences
  • Middle Aged
  • Nephrology. Urinary tract diseases
  • Nephropathies. Renovascular diseases. Renal failure
  • Original Report: Laboratory Investigation
  • Recombinant Proteins
  • Renal failure
  • Treatment Outcome
ispartof: American journal of nephrology, 2006, Vol.26 (3), p.276-280
description: Background/Aim: The urinary liver-type fatty-acid-binding protein (L-FABP) level reflects the clinical progression of chronic kidney disease. We conducted a study to determine whether administration of erythropoietin (EPO), which is produced in response to hypoxic stress, affects urinary protein excretion and L-FABP levels in patients with chronic renal failure (CRF) and anemia. Methods: The study was an interventional trial that included 20 anemic CRF patients (median serum creatinine level 2.0 mg/dl, range 1.3–2.9 mg/dl; median hemoglobin concentration 9.2 g/dl, range 8.2–9.8 g/dl; median estimated glomerular filtration rate 20.5 ml/min, range 15.0–28.0 ml/min; group A). Recombinant EPO (12,000 U twice/month) was given to these patients for 6 months. Urinary protein, L-FABP, 8-hydroxy-2′-deoxyguanosine, and hemoglobin levels were measured before and 3 and 6 months after treatment. Twenty nonanemic CRF patients were enrolled as controls (group B). Results: After 6 months, the hemoglobin level was increased as compared with the baseline level in group A treated with EPO (median 11.3 g/dl, range 9.3–13.8 g/dl, vs. median 9.2 g/dl, range 8.2–9.8 g/dl; p < 0.01) but not in the untreated group B (median 11.8 g/dl, range 10.2–13.0 g/dl, vs. median 12.1 g/dl, range 10.8–13.4 g/dl; not significant). The urinary protein excretion was decreased as compared with the baseline level in group A (median 1.2 g/day, range 0.6–1.9 g/day, vs. median 1.9 g/day, range 1.1–2.6 g/day; p < 0.01) but not in group B (median 1.4 g/day, range 0.7–2.2 g/day, vs. median 1.6 g/day, range 0.7–2.3 g/day; not significant). The urinary L-FABP level was also decreased as compared with the baseline level in group A (median 50.0 µg/g creatinine, range 7.5–90.0 µg/g creatinine, vs. median 115.0 µg/g creatinine, range 20.0–225.0 µg/g creatinine; p < 0.01) but not in group B (median 82.0 µg/g creatinine, range 15.5–158.0 µg/g creatinine, vs. median 76.0 µg/g creatinine, range 25.0–138.5 µg/g creatinine; not significant). The glomerular filtration rate changed little throughout the study period in either group. The urinary 8-hydroxy-2′-deoxyguanosine level was decreased as compared with the baseline level in group A (median 22.0 ng/mg creatinine, range 8.0–30.0 ng/mg creatinine, vs. median 38.5 ng/mg creatinine, range 14.0–68.0 ng/mg creatinine; p < 0.01) but not in group B (median 33.0 ng/mg creatinine, range 9.0–56.0 ng/mg creatinine, vs. median 30.0 ng/mg creatinine, range 10.0–54.0 ng/mg crea
language: eng
source: Alma/SFX Local Collection
identifier: ISSN: 0250-8095
fulltext: fulltext
issn:
  • 0250-8095
  • 1421-9670
url: Link


@attributes
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
RANK2.0066514
LOCALfalse
PrimoNMBib
record
control
sourceidproquest_cross
recordidTN_cdi_proquest_journals_236943470
sourceformatXML
sourcesystemPC
sourcerecordid68648373
originalsourceidFETCH-LOGICAL-c361t-2371b23dd6a1916b6cf90645414f3e3f8047f8ad892f7ba7aff97637456eb5c83
addsrcrecordideNptkV1rFDEUhoModq1e-AckCApejD35mGRyuS5bP1i0SHs9ZDNJmzqbbJOMsvjnTenQQjEEcvOc55y8B6HXBD4S0qoTqEcxxfgTtCCckkYJCU_RAmgLTQeqPUIvcr4GILQD-RwdESElldAt0N-1c9YUHB1ep0O5SnEfvS0-4BjwRfJBpwPe-N82NeeHvcWnupRDszR-aD75MPhwic9SLLYW1Humi7ehZPzHlyu8qrbgDf5pgx5rpR-nZLEOA14Gu_P6JXrm9Jjtq_k9Rhen6_PVl2bz4_PX1XLTGCZIaSiTZEvZMAhNFBFbYZwCwVtOuGOWuQ64dJ0eOkWd3GqpnVNSMMlbYbet6dgxen_n3ad4M9lc-p3Pxo6jDjZOuRed4B2TrIJvH4HXcUp1-NxTJhRnXEKFPtxBJsWck3X9Pvldjakn0N-uo79fR2XfzMJpu7PDAznnX4F3M6Cz0aNLOhifHziphCD8VnTyqKnxpYYdQ0k11_-2nj_9S6dLm-6Vy2_fKYAAKgAYrTn9A-ZRq5Q
sourcetypeAggregation Database
isCDItrue
recordtypearticle
pqid236943470
display
typearticle
titleEffect of Erythropoietin on Urinary Liver-Type Fatty-Acid-Binding Protein in Patients with Chronic Renal Failure and Anemia
sourceAlma/SFX Local Collection
creatorNakamura, Tsukasa ; Sugaya, Takeshi ; Kawagoe, Yasuhiro ; Suzuki, Tsukasa ; Ueda, Yoshihiko ; Koide, Hikaru
creatorcontribNakamura, Tsukasa ; Sugaya, Takeshi ; Kawagoe, Yasuhiro ; Suzuki, Tsukasa ; Ueda, Yoshihiko ; Koide, Hikaru
descriptionBackground/Aim: The urinary liver-type fatty-acid-binding protein (L-FABP) level reflects the clinical progression of chronic kidney disease. We conducted a study to determine whether administration of erythropoietin (EPO), which is produced in response to hypoxic stress, affects urinary protein excretion and L-FABP levels in patients with chronic renal failure (CRF) and anemia. Methods: The study was an interventional trial that included 20 anemic CRF patients (median serum creatinine level 2.0 mg/dl, range 1.3–2.9 mg/dl; median hemoglobin concentration 9.2 g/dl, range 8.2–9.8 g/dl; median estimated glomerular filtration rate 20.5 ml/min, range 15.0–28.0 ml/min; group A). Recombinant EPO (12,000 U twice/month) was given to these patients for 6 months. Urinary protein, L-FABP, 8-hydroxy-2′-deoxyguanosine, and hemoglobin levels were measured before and 3 and 6 months after treatment. Twenty nonanemic CRF patients were enrolled as controls (group B). Results: After 6 months, the hemoglobin level was increased as compared with the baseline level in group A treated with EPO (median 11.3 g/dl, range 9.3–13.8 g/dl, vs. median 9.2 g/dl, range 8.2–9.8 g/dl; p < 0.01) but not in the untreated group B (median 11.8 g/dl, range 10.2–13.0 g/dl, vs. median 12.1 g/dl, range 10.8–13.4 g/dl; not significant). The urinary protein excretion was decreased as compared with the baseline level in group A (median 1.2 g/day, range 0.6–1.9 g/day, vs. median 1.9 g/day, range 1.1–2.6 g/day; p < 0.01) but not in group B (median 1.4 g/day, range 0.7–2.2 g/day, vs. median 1.6 g/day, range 0.7–2.3 g/day; not significant). The urinary L-FABP level was also decreased as compared with the baseline level in group A (median 50.0 µg/g creatinine, range 7.5–90.0 µg/g creatinine, vs. median 115.0 µg/g creatinine, range 20.0–225.0 µg/g creatinine; p < 0.01) but not in group B (median 82.0 µg/g creatinine, range 15.5–158.0 µg/g creatinine, vs. median 76.0 µg/g creatinine, range 25.0–138.5 µg/g creatinine; not significant). The glomerular filtration rate changed little throughout the study period in either group. The urinary 8-hydroxy-2′-deoxyguanosine level was decreased as compared with the baseline level in group A (median 22.0 ng/mg creatinine, range 8.0–30.0 ng/mg creatinine, vs. median 38.5 ng/mg creatinine, range 14.0–68.0 ng/mg creatinine; p < 0.01) but not in group B (median 33.0 ng/mg creatinine, range 9.0–56.0 ng/mg creatinine, vs. median 30.0 ng/mg creatinine, range 10.0–54.0 ng/mg creatinine; not significant). Conclusion: EPO supplementation may ameliorate renal tubular damage, in part, due to a reduction of oxidative stress in CRF patients with anemia.
identifier
0ISSN: 0250-8095
1EISSN: 1421-9670
2DOI: 10.1159/000093934
3PMID: 16772708
4CODEN: AJNED9
languageeng
publisherBasel, Switzerland: Karger
subjectAdult ; Aged ; Anemia - etiology ; Anemia - prevention & control ; Anemia - urine ; Anemias. Hemoglobinopathies ; Biological and medical sciences ; Diseases of red blood cells ; Erythropoietin - therapeutic use ; Fatty Acid-Binding Proteins - urine ; Female ; Hematologic and hematopoietic diseases ; Hemoglobins - analysis ; Humans ; Kidney Failure, Chronic - complications ; Kidney Failure, Chronic - drug therapy ; Kidney Failure, Chronic - urine ; Male ; Medical sciences ; Middle Aged ; Nephrology. Urinary tract diseases ; Nephropathies. Renovascular diseases. Renal failure ; Original Report: Laboratory Investigation ; Recombinant Proteins ; Renal failure ; Treatment Outcome
ispartofAmerican journal of nephrology, 2006, Vol.26 (3), p.276-280
rights
02006 S. Karger AG, Basel
12006 INIST-CNRS
2Copyright 2006 S. Karger AG, Basel.
3Copyright (c) 2006 S. Karger AG, Basel
lds50peer_reviewed
citedbyFETCH-LOGICAL-c361t-2371b23dd6a1916b6cf90645414f3e3f8047f8ad892f7ba7aff97637456eb5c83
citesFETCH-LOGICAL-c361t-2371b23dd6a1916b6cf90645414f3e3f8047f8ad892f7ba7aff97637456eb5c83
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
thumbnail$$Usyndetics_thumb_exl
backlink
0$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17966144$$DView record in Pascal Francis
1$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16772708$$D View this record in MEDLINE/PubMed
search
creatorcontrib
0Nakamura, Tsukasa
1Sugaya, Takeshi
2Kawagoe, Yasuhiro
3Suzuki, Tsukasa
4Ueda, Yoshihiko
5Koide, Hikaru
title
0Effect of Erythropoietin on Urinary Liver-Type Fatty-Acid-Binding Protein in Patients with Chronic Renal Failure and Anemia
1American journal of nephrology
addtitleAm J Nephrol
descriptionBackground/Aim: The urinary liver-type fatty-acid-binding protein (L-FABP) level reflects the clinical progression of chronic kidney disease. We conducted a study to determine whether administration of erythropoietin (EPO), which is produced in response to hypoxic stress, affects urinary protein excretion and L-FABP levels in patients with chronic renal failure (CRF) and anemia. Methods: The study was an interventional trial that included 20 anemic CRF patients (median serum creatinine level 2.0 mg/dl, range 1.3–2.9 mg/dl; median hemoglobin concentration 9.2 g/dl, range 8.2–9.8 g/dl; median estimated glomerular filtration rate 20.5 ml/min, range 15.0–28.0 ml/min; group A). Recombinant EPO (12,000 U twice/month) was given to these patients for 6 months. Urinary protein, L-FABP, 8-hydroxy-2′-deoxyguanosine, and hemoglobin levels were measured before and 3 and 6 months after treatment. Twenty nonanemic CRF patients were enrolled as controls (group B). Results: After 6 months, the hemoglobin level was increased as compared with the baseline level in group A treated with EPO (median 11.3 g/dl, range 9.3–13.8 g/dl, vs. median 9.2 g/dl, range 8.2–9.8 g/dl; p < 0.01) but not in the untreated group B (median 11.8 g/dl, range 10.2–13.0 g/dl, vs. median 12.1 g/dl, range 10.8–13.4 g/dl; not significant). The urinary protein excretion was decreased as compared with the baseline level in group A (median 1.2 g/day, range 0.6–1.9 g/day, vs. median 1.9 g/day, range 1.1–2.6 g/day; p < 0.01) but not in group B (median 1.4 g/day, range 0.7–2.2 g/day, vs. median 1.6 g/day, range 0.7–2.3 g/day; not significant). The urinary L-FABP level was also decreased as compared with the baseline level in group A (median 50.0 µg/g creatinine, range 7.5–90.0 µg/g creatinine, vs. median 115.0 µg/g creatinine, range 20.0–225.0 µg/g creatinine; p < 0.01) but not in group B (median 82.0 µg/g creatinine, range 15.5–158.0 µg/g creatinine, vs. median 76.0 µg/g creatinine, range 25.0–138.5 µg/g creatinine; not significant). The glomerular filtration rate changed little throughout the study period in either group. The urinary 8-hydroxy-2′-deoxyguanosine level was decreased as compared with the baseline level in group A (median 22.0 ng/mg creatinine, range 8.0–30.0 ng/mg creatinine, vs. median 38.5 ng/mg creatinine, range 14.0–68.0 ng/mg creatinine; p < 0.01) but not in group B (median 33.0 ng/mg creatinine, range 9.0–56.0 ng/mg creatinine, vs. median 30.0 ng/mg creatinine, range 10.0–54.0 ng/mg creatinine; not significant). Conclusion: EPO supplementation may ameliorate renal tubular damage, in part, due to a reduction of oxidative stress in CRF patients with anemia.
subject
0Adult
1Aged
2Anemia - etiology
3Anemia - prevention & control
4Anemia - urine
5Anemias. Hemoglobinopathies
6Biological and medical sciences
7Diseases of red blood cells
8Erythropoietin - therapeutic use
9Fatty Acid-Binding Proteins - urine
10Female
11Hematologic and hematopoietic diseases
12Hemoglobins - analysis
13Humans
14Kidney Failure, Chronic - complications
15Kidney Failure, Chronic - drug therapy
16Kidney Failure, Chronic - urine
17Male
18Medical sciences
19Middle Aged
20Nephrology. Urinary tract diseases
21Nephropathies. Renovascular diseases. Renal failure
22Original Report: Laboratory Investigation
23Recombinant Proteins
24Renal failure
25Treatment Outcome
issn
00250-8095
11421-9670
fulltexttrue
rsrctypearticle
creationdate2006
recordtypearticle
recordideNptkV1rFDEUhoModq1e-AckCApejD35mGRyuS5bP1i0SHs9ZDNJmzqbbJOMsvjnTenQQjEEcvOc55y8B6HXBD4S0qoTqEcxxfgTtCCckkYJCU_RAmgLTQeqPUIvcr4GILQD-RwdESElldAt0N-1c9YUHB1ep0O5SnEfvS0-4BjwRfJBpwPe-N82NeeHvcWnupRDszR-aD75MPhwic9SLLYW1Humi7ehZPzHlyu8qrbgDf5pgx5rpR-nZLEOA14Gu_P6JXrm9Jjtq_k9Rhen6_PVl2bz4_PX1XLTGCZIaSiTZEvZMAhNFBFbYZwCwVtOuGOWuQ64dJ0eOkWd3GqpnVNSMMlbYbet6dgxen_n3ad4M9lc-p3Pxo6jDjZOuRed4B2TrIJvH4HXcUp1-NxTJhRnXEKFPtxBJsWck3X9Pvldjakn0N-uo79fR2XfzMJpu7PDAznnX4F3M6Cz0aNLOhifHziphCD8VnTyqKnxpYYdQ0k11_-2nj_9S6dLm-6Vy2_fKYAAKgAYrTn9A-ZRq5Q
startdate200607
enddate200607
creator
0Nakamura, Tsukasa
1Sugaya, Takeshi
2Kawagoe, Yasuhiro
3Suzuki, Tsukasa
4Ueda, Yoshihiko
5Koide, Hikaru
general
0Karger
1S. Karger AG
scope
0IQODW
1CGR
2CUY
3CVF
4ECM
5EIF
6NPM
7AAYXX
8CITATION
93V.
107QL
117QP
127RV
137T7
147U9
157X7
167XB
1788E
1888I
198AF
208AO
218FD
228FI
238FJ
248FK
25ABUWG
26AZQEC
27BENPR
28C1K
29DWQXO
30FR3
31FYUFA
32GHDGH
33GNUQQ
34H94
35HCIFZ
36K9.
37KB0
38M0S
39M1P
40M2P
41M7N
42NAPCQ
43P64
44PQEST
45PQQKQ
46PQUKI
47PRINS
48Q9U
49S0X
507X8
sort
creationdate200607
titleEffect of Erythropoietin on Urinary Liver-Type Fatty-Acid-Binding Protein in Patients with Chronic Renal Failure and Anemia
authorNakamura, Tsukasa ; Sugaya, Takeshi ; Kawagoe, Yasuhiro ; Suzuki, Tsukasa ; Ueda, Yoshihiko ; Koide, Hikaru
facets
frbrtype5
frbrgroupidcdi_FETCH-LOGICAL-c361t-2371b23dd6a1916b6cf90645414f3e3f8047f8ad892f7ba7aff97637456eb5c83
rsrctypearticles
prefilterarticles
languageeng
creationdate2006
topic
0Adult
1Aged
2Anemia - etiology
3Anemia - prevention & control
4Anemia - urine
5Anemias. Hemoglobinopathies
6Biological and medical sciences
7Diseases of red blood cells
8Erythropoietin - therapeutic use
9Fatty Acid-Binding Proteins - urine
10Female
11Hematologic and hematopoietic diseases
12Hemoglobins - analysis
13Humans
14Kidney Failure, Chronic - complications
15Kidney Failure, Chronic - drug therapy
16Kidney Failure, Chronic - urine
17Male
18Medical sciences
19Middle Aged
20Nephrology. Urinary tract diseases
21Nephropathies. Renovascular diseases. Renal failure
22Original Report: Laboratory Investigation
23Recombinant Proteins
24Renal failure
25Treatment Outcome
toplevel
0peer_reviewed
1online_resources
creatorcontrib
0Nakamura, Tsukasa
1Sugaya, Takeshi
2Kawagoe, Yasuhiro
3Suzuki, Tsukasa
4Ueda, Yoshihiko
5Koide, Hikaru
collection
0Pascal-Francis
1Medline
2MEDLINE
3MEDLINE (Ovid)
4MEDLINE
5MEDLINE
6PubMed
7CrossRef
8ProQuest Central (Corporate)
9Bacteriology Abstracts (Microbiology B)
10Calcium & Calcified Tissue Abstracts
11Nursing & Allied Health Database
12Industrial and Applied Microbiology Abstracts (Microbiology A)
13Virology and AIDS Abstracts
14Health & Medical Collection
15ProQuest Central (purchase pre-March 2016)
16Medical Database (Alumni Edition)
17Science Database (Alumni Edition)
18STEM Database
19ProQuest Pharma Collection
20Technology Research Database
21Hospital Premium Collection
22Hospital Premium Collection (Alumni Edition)
23ProQuest Central (Alumni) (purchase pre-March 2016)
24ProQuest Central (Alumni Edition)
25ProQuest Central Essentials
26ProQuest Central
27Environmental Sciences and Pollution Management
28ProQuest Central Korea
29Engineering Research Database
30Health Research Premium Collection
31Health Research Premium Collection (Alumni)
32ProQuest Central Student
33AIDS and Cancer Research Abstracts
34SciTech Premium Collection
35ProQuest Health & Medical Complete (Alumni)
36Nursing & Allied Health Database (Alumni Edition)
37Health & Medical Collection (Alumni Edition)
38Medical Database
39Science Database
40Algology Mycology and Protozoology Abstracts (Microbiology C)
41Nursing & Allied Health Premium
42Biotechnology and BioEngineering Abstracts
43ProQuest One Academic Eastern Edition
44ProQuest One Academic
45ProQuest One Academic UKI Edition
46ProQuest Central China
47ProQuest Central Basic
48SIRS Editorial
49MEDLINE - Academic
jtitleAmerican journal of nephrology
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
au
0Nakamura, Tsukasa
1Sugaya, Takeshi
2Kawagoe, Yasuhiro
3Suzuki, Tsukasa
4Ueda, Yoshihiko
5Koide, Hikaru
formatjournal
genrearticle
ristypeJOUR
atitleEffect of Erythropoietin on Urinary Liver-Type Fatty-Acid-Binding Protein in Patients with Chronic Renal Failure and Anemia
jtitleAmerican journal of nephrology
addtitleAm J Nephrol
date2006-07
risdate2006
volume26
issue3
spage276
epage280
pages276-280
issn0250-8095
eissn1421-9670
codenAJNED9
abstractBackground/Aim: The urinary liver-type fatty-acid-binding protein (L-FABP) level reflects the clinical progression of chronic kidney disease. We conducted a study to determine whether administration of erythropoietin (EPO), which is produced in response to hypoxic stress, affects urinary protein excretion and L-FABP levels in patients with chronic renal failure (CRF) and anemia. Methods: The study was an interventional trial that included 20 anemic CRF patients (median serum creatinine level 2.0 mg/dl, range 1.3–2.9 mg/dl; median hemoglobin concentration 9.2 g/dl, range 8.2–9.8 g/dl; median estimated glomerular filtration rate 20.5 ml/min, range 15.0–28.0 ml/min; group A). Recombinant EPO (12,000 U twice/month) was given to these patients for 6 months. Urinary protein, L-FABP, 8-hydroxy-2′-deoxyguanosine, and hemoglobin levels were measured before and 3 and 6 months after treatment. Twenty nonanemic CRF patients were enrolled as controls (group B). Results: After 6 months, the hemoglobin level was increased as compared with the baseline level in group A treated with EPO (median 11.3 g/dl, range 9.3–13.8 g/dl, vs. median 9.2 g/dl, range 8.2–9.8 g/dl; p < 0.01) but not in the untreated group B (median 11.8 g/dl, range 10.2–13.0 g/dl, vs. median 12.1 g/dl, range 10.8–13.4 g/dl; not significant). The urinary protein excretion was decreased as compared with the baseline level in group A (median 1.2 g/day, range 0.6–1.9 g/day, vs. median 1.9 g/day, range 1.1–2.6 g/day; p < 0.01) but not in group B (median 1.4 g/day, range 0.7–2.2 g/day, vs. median 1.6 g/day, range 0.7–2.3 g/day; not significant). The urinary L-FABP level was also decreased as compared with the baseline level in group A (median 50.0 µg/g creatinine, range 7.5–90.0 µg/g creatinine, vs. median 115.0 µg/g creatinine, range 20.0–225.0 µg/g creatinine; p < 0.01) but not in group B (median 82.0 µg/g creatinine, range 15.5–158.0 µg/g creatinine, vs. median 76.0 µg/g creatinine, range 25.0–138.5 µg/g creatinine; not significant). The glomerular filtration rate changed little throughout the study period in either group. The urinary 8-hydroxy-2′-deoxyguanosine level was decreased as compared with the baseline level in group A (median 22.0 ng/mg creatinine, range 8.0–30.0 ng/mg creatinine, vs. median 38.5 ng/mg creatinine, range 14.0–68.0 ng/mg creatinine; p < 0.01) but not in group B (median 33.0 ng/mg creatinine, range 9.0–56.0 ng/mg creatinine, vs. median 30.0 ng/mg creatinine, range 10.0–54.0 ng/mg creatinine; not significant). Conclusion: EPO supplementation may ameliorate renal tubular damage, in part, due to a reduction of oxidative stress in CRF patients with anemia.
copBasel, Switzerland
pubKarger
pmid16772708
doi10.1159/000093934
tpages5